268 related articles for article (PubMed ID: 32250304)
21. Disease progression and costs at the 3-year follow-up of the GERAS-US study.
Chandler JM; Rentz DM; Zagar A; Kim Y; Schwartz RL; Fillit H
Alzheimers Dement (Amst); 2023; 15(2):e12430. PubMed ID: 37091310
[TBL] [Abstract][Full Text] [Related]
22. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
[TBL] [Abstract][Full Text] [Related]
23. Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
Dauphinot V; Potashman M; Levitchi-Benea M; Su R; Rubino I; Krolak-Salmon P
Alzheimers Res Ther; 2022 Feb; 14(1):34. PubMed ID: 35151368
[TBL] [Abstract][Full Text] [Related]
24. The effects of dependence and function on costs of care for Alzheimer's disease and mild cognitive impairment in Ireland.
Gillespie P; O'Shea E; Cullinan J; Lacey L; Gallagher D; Ni Mhaolain A;
Int J Geriatr Psychiatry; 2013 Mar; 28(3):256-64. PubMed ID: 23386588
[TBL] [Abstract][Full Text] [Related]
25. The economics of mild cognitive impairment.
Lin PJ; Neumann PJ
Alzheimers Dement; 2013 Jan; 9(1):58-62. PubMed ID: 23141385
[TBL] [Abstract][Full Text] [Related]
26. Determinants of Medical Direct Costs of Care among Patients of a Memory Center.
Dauphinot V; Garnier-Crussard A; Moutet C; Delphin-Combe F; Späth HM; Krolak-Salmon P
J Prev Alzheimers Dis; 2021; 8(3):351-361. PubMed ID: 34101794
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
[TBL] [Abstract][Full Text] [Related]
28. Caregivers' Sense of Coherence: Implications on Direct and Indirect Costs of Dementia Care.
Turró-Garriga O; Viñas-Díez V; Conde-Sala JL; Calvó-Perxas L; Cullell-Juncà M; Mas-Vall-Llosera G; Flaqué M; Turon-Estrada A; Juvinyà-Canal D; Mioshi E; Garre-Olmo J
J Alzheimers Dis; 2020; 78(1):117-126. PubMed ID: 32925037
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
[TBL] [Abstract][Full Text] [Related]
30. Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis.
Tariot PN; Boada M; Lanctôt KL; Hahn-Pedersen J; Dabbous F; Udayachalerm S; Raket LL; Halchenko Y; Michalak W; Weidner W; Cummings J
Alzheimers Res Ther; 2024 Feb; 16(1):36. PubMed ID: 38355706
[TBL] [Abstract][Full Text] [Related]
31. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
32. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
33. Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
Reed C; Belger M; Dell'Agnello G; Kahle-Wrobleski K; Sethuraman G; Hake A; Raskin J; Henley D
Alzheimers Res Ther; 2018 Apr; 10(1):36. PubMed ID: 29615123
[TBL] [Abstract][Full Text] [Related]
34. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
[TBL] [Abstract][Full Text] [Related]
35. Cross sectional observational study on the societal costs of Alzheimer's disease.
Mesterton J; Wimo A; By A; Langworth S; Winblad B; Jönsson L
Curr Alzheimer Res; 2010 Jun; 7(4):358-67. PubMed ID: 19939223
[TBL] [Abstract][Full Text] [Related]
36. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.
Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A;
J Nutr Health Aging; 2010 Oct; 14(8):648-54. PubMed ID: 20922341
[TBL] [Abstract][Full Text] [Related]
37. 2022 Alzheimer's disease facts and figures.
Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
[TBL] [Abstract][Full Text] [Related]
38. Difference in determinants of caregiver burden between amnestic mild cognitive impairment and mild Alzheimer's disease.
Ikeda C; Terada S; Oshima E; Hayashi S; Okahisa Y; Takaki M; Inagaki M; Yokota O; Uchitomi Y
Psychiatry Res; 2015 Mar; 226(1):242-6. PubMed ID: 25631688
[TBL] [Abstract][Full Text] [Related]
39. The financial burden and health care utilization patterns associated with amnestic mild cognitive impairment.
Ton TGN; DeLeire T; May SG; Hou N; Tebeka MG; Chen E; Chodosh J
Alzheimers Dement; 2017 Mar; 13(3):217-224. PubMed ID: 27693186
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
